sepsis

Doctors accuse Eli Lilly of trying to buy regulatory influence to benefit sepsis drug

Friday, October 20, 2006 by: Jessica Fraser
Tags: sepsis, Eli Lilly, drug marketing

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
The five biggest lies about Ebola being pushed by government and mass media
Why does the CDC own a patent on Ebola 'invention?'
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Oregon man serving prison sentence for collecting rainwater on his own property
Russia taking McDonald's to court, threatens countrywide shutdown
Global warming data FAKED by government to fit climate change fictions
The best way to help your body protect itself against Ebola (or any virus or bacteria)
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
BREAKING: CDC whistleblower confesses to MMR vaccine research fraud in historic public statement
Monsanto's seed imperialism halted in Canada thanks to massive protests
Cannabis dissolves cancerous tumor in young infant, deemed a 'miracle baby' by physician
Top ten things you need to do NOW to protect yourself from an uncontrolled Ebola outbreak

Delicious
(NaturalNews) Three federal researchers yesterday said drug giant Eli Lilly and Co. might have improperly influenced guidelines on the treatment of the deadly infection sepsis for the purpose of selling more of its expensive sepsis drug, Xigris.

Sepsis -- a system-wide infection that produces an overwhelming and frequently deadly immune response in the body -- infects roughly 750,000 Americans every year. Up to 70 percent die of septic shock from the infection, while as many as 30 percent die from severe sepsis.

Though antibiotics can be used to cure sepsis, they can be slow to work. Lilly developed Xigris -- a genetically engineered human protein known as recombinant human activated protein C -- to help control the body's often deadly immune response to the infection. Xigris was tested in a single trial and found to reduce sepsis deaths from 44 percent to 31 percent among patients with the highest risk of death.

The federal researchers accused Lilly of trying to influence the sepsis treatment guidelines to benefit prescriptions of Xigris by hiring a marketing firm and paying ethicists and doctors to launch a campaign about how to choose which emergency room patients suffering from sepsis should receive Xigris. Sales of Xigris -- which fell short of its "blockbuster" projections -- were less than a quarter of expectations.

The company claimed its Xigris campaign was strictly educational, with the goal of ensuring only the appropriate patients were treated with the drug.

Dr. Peter Eichacker -- a panel adviser who voted against FDA approval of Xigris, which can cause bleeding -- of the National Institutes of Health, along with NIH staff members Dr. Charles Natanson and Dr. Robert Danner, charged that Lilly's campaign to influence the guidelines added up to "an extension of a pharmaceutical marketing campaign."

The three NIH researchers accused the drug firm of spreading word via marketing campaigns that Xigris "was being rationed and physicians were being 'systematically forced' to decide who would live and who would die," they wrote in a letter to the New England Journal of Medicine.

The researchers also said Lilly approved a $1.8 million grant to a group of doctors and ethicists to crease a task force for addressing ethical issues raised by rationing Xigris in the emergency room. The company also created a "Surviving Sepsis" campaign to raise awareness of severe sepsis and bring attention to the development of treatment guidelines, the researchers wrote.

###

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.